[On the dose-effect relationship in the therapy with piracetam (author's transl)]. 1976

J H Kretschmar, and C H Kretschmar

The effect of piracetam therapy with different dosages was studied in a double blind trial against placebo on its effect in psychoorganic syndrome of old age. 78 patients (61 females, 17 males) on the average of 73.2 years, showed statistically significant differences between piracetam therapy at a dosage of 3 X 1600 mg per day und placebo after a six week peroral therapy while no statistically significant differences between piracetam therapy at a dosage of 3X800 mg per day and placebo were found.

UI MeSH Term Description Entries
D008297 Male Males
D010889 Piracetam A compound suggested to be both a nootropic and a neuroprotective agent. 2-Pyrrolidone-N-Acetamide,Avigilen,Axonyl,Cerebroforte,Cerepar N,Ciclofalina,Cuxabrain,Dinagen,Gabacet,Geram,Memo-Puren,Nootrop,Nootropil,Nootropyl,Normabraïn,Piracebral,Piracetam AbZ,Piracetam-RPh,Piracetrop,Pirazetam,Pyracetam,Pyramem,Sinapsan,UCB-6215,Memo Puren,Piracetam RPh,UCB 6215,UCB6215
D011760 Pyrrolidinones A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed) Pyrrolidinone,Pyrrolidone,Pyrrolidones
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J H Kretschmar, and C H Kretschmar
September 1978, Strahlentherapie,
J H Kretschmar, and C H Kretschmar
November 1976, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
J H Kretschmar, and C H Kretschmar
January 1982, Aktuelle Gerontologie,
J H Kretschmar, and C H Kretschmar
April 1981, Ceskoslovenska psychiatrie,
J H Kretschmar, and C H Kretschmar
April 1980, Ceskoslovenska psychiatrie,
J H Kretschmar, and C H Kretschmar
November 1980, Sangyo igaku. Japanese journal of industrial health,
J H Kretschmar, and C H Kretschmar
January 1977, Arzneimittel-Forschung,
J H Kretschmar, and C H Kretschmar
September 1973, Praxis der Pneumologie,
J H Kretschmar, and C H Kretschmar
May 1982, Deutsche medizinische Wochenschrift (1946),
J H Kretschmar, and C H Kretschmar
January 1978, Acta neurologica Belgica,
Copied contents to your clipboard!